Reusable pen aging and lifecycle verification
Reusable devices need evidence across their intended service life, not only when new.
Evidence approachAging and lifecycle statements follow PubMed-indexed studies of reusable injection devices, including the cycle and storage assumptions each study stated.
What the research found
A small study compared 11 new and 11 patient-used reusable pens at 8- and 32-unit doses. Mean differences were small, but the study reported statistically significant differences and several individual 32-unit results below the tested ISO range. The authors called for larger studies.
Engineering interpretationLifecycle verification can include dose setting and delivery after repeated cycles, cleaning, handling, cartridge replacement, storage and environmental exposure. Acceptance criteria should be defined before testing.
Connection to Penacta
For Penacta reusable platforms, the intended number of cycles, service conditions and replaceable-container process should shape verification. This external study is a design input, not evidence for our catalog devices.
Research basis
Yücel et al. Dose accuracy of new versus used NovoPen 4 insulin pens. PMID 22866889.Sources reviewed
Peer reviewed records used to frame the article and its limitations
Define the reusable lifecycle
Set expected cycles and handling conditions before verification.
View a reusable platform →